Canaccord raised the firm’s price target on DexCom (DXCM) to $106 from $103 and keeps a Buy rating on the shares. The firm said they reported a good Q1, beating total and US revenue estimates, while short of OUS estimates but showing strong organic growth OUS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: